These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 26460999

  • 1. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
    Cederkrantz E, Andersson H, Bernhardt P, Bäck T, Hultborn R, Jacobsson L, Jensen H, Lindegren S, Ljungberg M, Magnander T, Palm S, Albertsson P.
    Int J Radiat Oncol Biol Phys; 2015 Nov 01; 93(3):569-76. PubMed ID: 26460999
    [Abstract] [Full Text] [Related]

  • 2. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R.
    J Nucl Med; 2009 Jul 01; 50(7):1153-60. PubMed ID: 19525452
    [Abstract] [Full Text] [Related]

  • 3. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with 211At-MX35-F(ab')2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival.
    Bäck T, Chouin N, Lindegren S, Kahu H, Jensen H, Albertsson P, Palm S.
    J Nucl Med; 2017 Apr 01; 58(4):598-604. PubMed ID: 27688477
    [Abstract] [Full Text] [Related]

  • 4. Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations.
    Hallqvist A, Bergmark K, Bäck T, Andersson H, Dahm-Kähler P, Johansson M, Lindegren S, Jensen H, Jacobsson L, Hultborn R, Palm S, Albertsson P.
    J Nucl Med; 2019 Aug 01; 60(8):1073-1079. PubMed ID: 30683761
    [Abstract] [Full Text] [Related]

  • 5. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
    Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.
    Nucl Med Biol; 2006 Nov 01; 33(8):1065-72. PubMed ID: 17127181
    [Abstract] [Full Text] [Related]

  • 6. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.
    Frost SH, Bäck T, Chouin N, Jensen H, Hultborn R, Jacobsson L, Lindegren S.
    Cancer Biother Radiopharm; 2011 Dec 01; 26(6):727-36. PubMed ID: 22087606
    [Abstract] [Full Text] [Related]

  • 7. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L.
    J Nucl Med; 2005 Dec 01; 46(12):2061-7. PubMed ID: 16330571
    [Abstract] [Full Text] [Related]

  • 8. Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.
    Bäck T, Haraldsson B, Hultborn R, Jensen H, Johansson ME, Lindegren S, Jacobsson L.
    Cancer Biother Radiopharm; 2009 Dec 01; 24(6):649-58. PubMed ID: 20025544
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L.
    J Nucl Med; 2005 Nov 01; 46(11):1907-15. PubMed ID: 16269606
    [Abstract] [Full Text] [Related]

  • 10. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
    Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.
    J Nucl Med; 2006 Aug 01; 47(8):1342-50. PubMed ID: 16883015
    [Abstract] [Full Text] [Related]

  • 11. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
    Elgqvist J, Andersson H, Bernhardt P, Bäck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):1228-37. PubMed ID: 17145538
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.
    Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung NK, Larson SM.
    Nucl Med Biol; 1996 Jan 15; 23(1):1-8. PubMed ID: 9004907
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
    Andersson H, Palm S, Lindegren S, Bäck T, Jacobsson L, Leser G, Horvath G.
    Anticancer Res; 2001 Jan 15; 21(1A):409-12. PubMed ID: 11299770
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 15; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 15. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct 15; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 16. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG, Fisher DR, Gopal AK, Durack LD, Press OW, Eary JF.
    J Nucl Med; 2004 Jun 15; 45(6):1059-64. PubMed ID: 15181141
    [Abstract] [Full Text] [Related]

  • 17. Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results.
    Breitz HB, Durham JS, Fisher DR, Weiden PL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5817s-5822s. PubMed ID: 7493352
    [Abstract] [Full Text] [Related]

  • 18. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
    Rajendran JG, Gopal AK, Fisher DR, Durack LD, Gooley TA, Press OW.
    J Nucl Med; 2008 May 01; 49(5):837-44. PubMed ID: 18413376
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody.
    Breitz HB, Durham JS, Fisher DR, Weiden PL, DeNardo GL, Goodgold HM, Nelp WB.
    J Nucl Med; 1995 May 01; 36(5):754-61. PubMed ID: 7738644
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A, Mulders P, Oosterwijk E, Buijs W, Corstens F, Boerman O, Oyen W.
    Cancer Biother Radiopharm; 2004 Aug 01; 19(4):466-77. PubMed ID: 15453961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.